Patient Perspectives Regarding the Value of Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma/Mycosis Fungoides A Pilot Study
被引:17
|
作者:
Yu, James B.
论文数: 0引用数: 0
h-index: 0
机构:
Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USAYale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
Yu, James B.
[1
]
Khan, Anwar M.
论文数: 0引用数: 0
h-index: 0
机构:
Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
Yale New Haven Med Ctr, New Haven, CT 06504 USAYale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
Khan, Anwar M.
[1
,2
]
Jones, Glenn W.
论文数: 0引用数: 0
h-index: 0
机构:
Credit Valley Hosp, Peel Reg Oncol Program, Mississauga, ON, CanadaYale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
Jones, Glenn W.
[3
]
Reavely, Margaret M.
论文数: 0引用数: 0
h-index: 0
机构:
Yale New Haven Med Ctr, New Haven, CT 06504 USAYale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
Reavely, Margaret M.
[2
]
Wilson, Lynn D.
论文数: 0引用数: 0
h-index: 0
机构:
Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
Yale New Haven Med Ctr, New Haven, CT 06504 USAYale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
Wilson, Lynn D.
[1
,2
]
机构:
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
[2] Yale New Haven Med Ctr, New Haven, CT 06504 USA
[3] Credit Valley Hosp, Peel Reg Oncol Program, Mississauga, ON, Canada
CTCL;
radiation oncology;
TSEBT;
total skin electron beam therapy;
cutaneous lymphoma;
QUALITY;
LYMPHOMAS;
D O I:
10.1097/COC.0b013e3181841f5c
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Purpose: Cutaneous T-cell lymphoma (CTCL) represents a group of lymphoid malignancies involving the skin with mycosis fungoides being most common. This prospective study was initiated to evaluate perceptions of total skin electron beam therapy (TSEBT) by patients with mycosis fungoides who had failed at least 3 prior therapies. Materials and Methods: Before the start of TSEBT, at I month and 6 months after the completion of treatment, patients completed an anonymous questionnaire for each of the prior therapies and for TSEBT. It identified the following: (1) success of the therapy, (2) difficulty in the therapy, (3) ability to recover from the therapy, (4) risk/benefit ratio of the therapy, and (5) willingness to repeat the therapy or therapies in question. Mean values for each question were compared using the paired t test. Results: Thirteen patients were enrolled in the study. At 1- and 6-months posttreatment, patients thought that TSEBT was more difficult to undergo and recover from in comparison to other therapies. At 6-months posttreatment, patients also opposed the repeat therapy with TSEBT compared with other treatments. Patients perceived TSEBT as more successful than other therapies, but this difference in perception was not statistically significant. Conclusions: TSEBT is perceived by patients to be a successful treatment. TSEBT is thought to be a difficult treatment to undergo and recover from compared with other treatments.